Received Sep 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | AS4G9 | — |
Late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 70-year-old male patient who received Herpes zoster (Shingrix) (batch number AS4G9) for prophylaxis. Previously administered products included Shingrix (received 1st dose of vaccine on 1st JAN 2018). On 29-SEP-2022, the patient received the 2nd dose of Shingrix. On 29-SEP-2022, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 09-SEP-2025 Pharmacist wanted to know if they have to revaccinate/restart patient's vaccination schedule or what to do in this case. The patient was planning on receiving another dose at the time of reporting or day after reporting. Vaccination dates, vaccine detail (only lot number was provided for dose administered on twenty twenty-two) and patient demographics were obtained in this call. No further information was obtained in this call.